QQQ   296.14 (-3.28%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   296.14 (-3.28%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   296.14 (-3.28%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
QQQ   296.14 (-3.28%)
AAPL   142.92 (-4.23%)
MSFT   257.02 (-3.67%)
FB   196.03 (-3.25%)
GOOGL   2,263.09 (-2.85%)
AMZN   2,179.73 (-5.53%)
TSLA   729.31 (-4.24%)
NVDA   173.40 (-4.60%)
BABA   89.10 (-3.14%)
NIO   16.13 (-3.01%)
AMD   98.51 (-3.86%)
CGC   5.74 (-2.55%)
MU   71.75 (-3.67%)
T   20.44 (-0.63%)
GE   75.52 (-1.15%)
F   12.96 (-4.21%)
DIS   105.57 (-2.83%)
AMC   13.39 (+3.80%)
PFE   50.42 (-1.79%)
PYPL   78.13 (-2.03%)
NFLX   182.51 (-4.22%)
NASDAQ:ADAG

Adagene (ADAG) Stock Forecast, Price & News

$2.88
-0.09 (-3.03%)
(As of 05/18/2022 11:53 AM ET)
Add
Compare
Today's Range
$2.88
$2.88
50-Day Range
$2.94
$4.87
52-Week Range
$2.89
$20.98
Volume
50 shs
Average Volume
19,479 shs
Market Capitalization
$126.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.67
30 days | 90 days | 365 days | Advanced Chart
Receive ADAG News and Ratings via Email

Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter.

Adagene logo

About Adagene

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Headlines

Adagene (NASDAQ:ADAG) Trading Down 1.4%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADAG
Fax
N/A
Employees
198
Year Founded
N/A

Sales & Book Value

Annual Sales
$10.18 million
Book Value
$3.59 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$126.12 million
Optionable
Not Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

816th out of 1,426 stocks

Pharmaceutical Preparations Industry

398th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Adagene (NASDAQ:ADAG) Frequently Asked Questions

Is Adagene a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Adagene stock.
View analyst ratings for Adagene
or view top-rated stocks.

What price target have analysts set for ADAG?

1 brokers have issued 1 year target prices for Adagene's shares. Their forecasts range from $15.00 to $15.00. On average, they anticipate Adagene's stock price to reach $15.00 in the next year. This suggests a possible upside of 420.8% from the stock's current price.
View analysts' price targets for Adagene
or view top-rated stocks among Wall Street analysts.

Who are Adagene's key executives?
Adagene's management team includes the following people:
  • Dr. Peter P. Luo Ph.D., Co-Founder, CEO & Chairman (Age 56)
  • Mr. Man Kin Tam M.B.A., CFO & Director (Age 45)
  • Dr. Fangyong Du Ph.D., Chief Technology Officer (Age 52)
  • Dr. Jc Xu M.D., Ph.D., Chief Scientific Officer (Age 57)
  • Ms. Ami Celeste Knoefler, VP of Investor Relations & Corp. Communications
  • Dr. Yu Ren Ph.D., Chief Strategy & Corp. Devel. Officer (Age 47)
  • Ms. Ling Zhou, Sr. Director of HR
  • Dr. Qinghai Zhao, Chief Manufacturing Officer (Age 61)
  • Ms. Yan Li M.B.A., Sr. VP of Bioinformatics & Information Technology (Age 47)
  • Ms. Xiaohong She, Sr. VP & Head of Clinical Operations (Age 55)
When did Adagene IPO?

(ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies acted as the underwriters for the IPO and China Renaissance was co-manager.

What is Adagene's stock symbol?

Adagene trades on the NASDAQ under the ticker symbol "ADAG."

Who are Adagene's major shareholders?

Adagene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Strategic Vision Investment Ltd (1.78%), Matthews International Capital Management LLC (1.49%) and E Fund Management Co. Ltd. (0.04%).

Which major investors are selling Adagene stock?

ADAG stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, and E Fund Management Co. Ltd..

Which major investors are buying Adagene stock?

ADAG stock was purchased by a variety of institutional investors in the last quarter, including Strategic Vision Investment Ltd.

How do I buy shares of Adagene?

Shares of ADAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adagene's stock price today?

One share of ADAG stock can currently be purchased for approximately $2.88.

How much money does Adagene make?

Adagene has a market capitalization of $126.12 million and generates $10.18 million in revenue each year.

How many employees does Adagene have?

Adagene employs 198 workers across the globe.

What is Adagene's official website?

The official website for Adagene is www.adagene.com.

How can I contact Adagene?

Adagene's mailing address is 4F BUILDING C14 NO. 218 XINGHU STREET SUZHOU INDUSTRIAL PARK, JIANGSU F4, 215123. The company can be reached via phone at 86-512-8777-3632 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.